Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | BTK L528W |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| BTK L528W | diffuse large B-cell lymphoma | resistant | Pirtobrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK L528W demonstrated resistance to Jaypirca (pirtobrutinib) in culture (PMID: 35196427). | 35196427 | |
| BTK L528W | chronic lymphocytic leukemia | predicted - resistant | Pirtobrutinib | Case Reports/Case Series | Actionable | In a clinical case study, 2 patients with chronic lymphocytic leukemia who previously responded to Jaypirca (pirtobrutinib) treatment were found to have acquired BTK L528W upon disease progression (PMID: 35196427). | 35196427 | |
| BTK L528W | diffuse large B-cell lymphoma | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK L528W demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 35196427). | 35196427 | |
| BTK L528W | diffuse large B-cell lymphoma | resistant | Fenebrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK L528W demonstrated resistance to Fenebrutinib (GDC-0853) in culture (PMID: 35196427). | 35196427 | |
| BTK L528W | diffuse large B-cell lymphoma | resistant | Vecabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK L528W demonstrated resistance to Vecabrutinib (SNS-062) in culture (PMID: 35196427). | 35196427 | |
| BTK L528W | diffuse large B-cell lymphoma | predicted - sensitive | NX-5948 | Preclinical - Cell culture | Actionable | In a preclinical study, NX-5948 inhibited Btk signaling and proliferation of a diffuse large B-cell lymphoma cell line expressing BTK L528W in culture (Cancer Res (2023) 83 (7_Supplement): 2850). | detail... | |
| BTK L528W | chronic lymphocytic leukemia | predicted - resistant | Tirabrutinib | Case Reports/Case Series | Actionable | In Phase I trials, two patients with chronic lymphocytic leukemia progressed on treatment with Tirabrutinib (ONO-4059) and each were subsequently found to have acquired BTK L528W (PMID: 37257190; NCT01659255 and NCT02457598). | 37257190 | |
| BTK L528W | diffuse large B-cell lymphoma | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, diffuse large B-cell lymphoma cell lines expressing BTK L528W demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 36183831). | 36183831 | |
| BTK L528W | diffuse large B-cell lymphoma | sensitive | NX-2127 | Preclinical - Cell culture | Actionable | In a preclinical study, NX-2127 inhibited viability of a diffuse large B-cell lymphoma cell line expressing BTK L528W in culture (PMID: 38301010). | 38301010 | |
| BTK L528W | diffuse large B-cell lymphoma | resistant | Pirtobrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK L528W demonstrated resistance to Jaypirca (pirtobrutinib) in culture (PMID: 38301010). | 38301010 | |
| BTK L528W | diffuse large B-cell lymphoma | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK L528W demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 38301010). | 38301010 | |
| BTK L528W | diffuse large B-cell lymphoma | resistant | Zanubrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK L528W demonstrated resistance to Brukinsa (zanubrutinib) in culture (PMID: 38301010). | 38301010 | |
| BTK L528W | lymphoma | predicted - sensitive | DZD8586 | Preclinical - Cell culture | Actionable | In a preclinical study, DZD8586 inhibited proliferation of lymphoma cells expressing BTK L528W in culture (Blood (2023) 142 (Supplement 1): 2822). | detail... |